Seed · Biotech · Oslo, Norway · Founded 2018 · 10–15 employees
ClexBio is developing breakthrough bioengineered human tissue for medical transplants using their proprietary CLEX hydrogel technology platform. The company has successfully created bioengineered veins in partnership with CSEM and developed an automated bioreactor for scalable manufacturing. They've secured $2.2M in seed funding in 2021 and received recent investment from EQT Foundation to advance their tissue engineering capabilities. ClexBio is focusing on treating chronic venous insufficiency and liver disease, with ambitions to expand into multiple tissue therapy applications.
No open roles listed right now.